| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Revance Therapeutics, Inc.$3.65
0 (0%)
C 43Pipeline Score Fair Value Biotech · Clinical
Market Cap
379.98 M
EPS
-1.92
P/E Ratio
-
Value Trade
15.06 M
-0.55 %
Week
18.18 %
1 Month
-38.31 %
3 Month
-2.15 %
6 Month
-83.21 %
5 Year
-82.67 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
4.12 M
52 Week Range
2.30 - 7.56
% held by Insiders
0.09 %
% held by Institutions
0.87 %
Enterprise Value
682.26 M
Total Shares
104.39 M
Short %
0.05 %
Float Shares
91.29 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | DaxibotulinumtoxinA for Injection (later DAXXIFY) | PDUFA Date | PDUFA | CRL | – | – | – |
— | DaxibotulinumtoxinA for Injection (later DAXXIFY) | PDUFA Date | PDUFA | CRL | – | – | – |
— | DaxibotulinumtoxinA for Injection (later DAXXIFY) | PDUFA Date | PDUFA | CRL | – | – | – |
Drug Pipeline Intelligence
C43
Pipeline Score $711M
Pipeline ValueFair Value
Valuation Signal9
Drugs Scored1.9x
rNPV / MCap Top 66%
Micro Cap (rank 315 of 923)
Percentile RankRevance Therapeutics, Inc. carries a moderate pipeline score (43/100), with $2.5B risk-adjusted pipeline value, led by Botulinum Toxin Type A in Skin Aging (Phase 3), across $114B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Botulinum Toxin Type A Small molecule | Skin Aging | Phase 3 | NCT01940991 | 58% | $1.5B | COMPLETED | 779 | - | - | Nov 1, 2013 | - | Jan 31, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
DaxibotulinumtoxinA for Injection | Cervical Dystonia | Phase 3 | 2020-10-14 | 125 Unit change from baseline: 12.7; 250 Unit change from baseline: 10.9; placebo change from baseline: 4.3; p value 125 Unit: <0.0001; p value 250 Unit: 0.0006; median duration 125 Unit: 24; median duration 250 Unit: 20.3 Read More | Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia - Trial met primary and all secondary endpoints for both 125- and 250-Unit doses with high statistical Read More | |
DaxibotulinumtoxinA for Injection | Cervical Dystonia | Phase 3 | 2020-10-14 | 125 Unit change from baseline: 12.7; 250 Unit change from baseline: 10.9; placebo change from baseline: 4.3; p value 125 Unit: <0.0001; p value 250 Unit: 0.0006; median duration 125 Unit: 24; median duration 250 Unit: 20.3 Read More | Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia - Trial met primary and all secondary endpoints for both 125- and 250-Unit doses with high statistical Read More | |
DaxibotulinumtoxinA for Injection | Cervical Dystonia | Phase 3 | 2020-10-14 | 125 Unit change from baseline: 12.7; 250 Unit change from baseline: 10.9; placebo change from baseline: 4.3; p value 125 Unit: <0.0001; p value 250 Unit: 0.0006; median duration 125 Unit: 24; median duration 250 Unit: 20.3 Read More | Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia - Trial met primary and all secondary endpoints for both 125- and 250-Unit doses with high statistical Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RVNC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RVNC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How RVNC ranks across every disease it competes inCompetitive Position is a premium feature
See how RVNC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial